Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: patron_anejo_por_favor who wrote (119590)	9/5/2001 11:08:19 AM
From: patron_anejo_por_favor	Read Replies (1) \| Respond to of 436258

Sold a few Dow poots, the put/calls this am are looking a bit frothy (for bears): cboe.com

To: patron_anejo_por_favor who wrote (119590)	9/5/2001 11:35:07 AM
From: yard_man	Respond to of 436258

has this POS traded yet? siliconinvestor.com

To: patron_anejo_por_favor who wrote (119590)	9/6/2001 1:39:49 AM
From: fedhead	Respond to of 436258

And lets not forget BZH. Anindo

To: patron_anejo_por_favor who wrote (119590)	9/6/2001 6:36:36 AM
From: Bocor	Respond to of 436258

MDT: ooops...another overvalued pig should bite the dust this am: DJ Medtronic/$1.5B Senior Convertible -2: Premium 35%-40% 05 Sep 16:54 NEW YORK (Dow Jones)--Medtronic Inc. (MDT) plans to price $1.5 billion in senior convertible notes late Wednesday via joint bookrunners Goldman Sachs, Morgan Stanley and Banc of America Securities, according to people familiar with the deal. The 20-year notes are expected to be issued at par and include a coupon of between 1.0% and 1.5%, with conversion premium of 35% to 40%, sources said. The deal has an overallotment option, or greenshoe, of 15%. The notes will be noncallable for five years and puttable in years one, three, five, seven, 10 and 15. The deal also has contingent conversion and contingent payment features. Thus, investors won't be able to convert the notes unless the company's stock price appreciates to 110% above the accreted conversion price, sources said. Also, the company won't pay interest on the notes unless - after the five years of hard-call protection - the bond price appreciates to 110% above the accreted conversion price, they said. The notes are expected to be rated double-A by Standard & Poor's and A1 by Moody's Investors Service. Medtronic, a medical technology company, is based in Minneapolis.